Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab Extension Study in RA
NCT01256736Phase 3Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Mar 2010
- Primary completion
- Dec 2011
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of tocilizumab in rheumatoid arthritis (RA), sponsored by JW Pharmaceutical Corporation. Started Mar 2010; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01256736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01256736.